These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37069602)

  • 1. Cost-effectiveness of the screen-and-treat strategies using HPV test linked to thermal ablation for cervical cancer prevention in China: a modeling study.
    Zhao XL; Zhao S; Xia CF; Hu SY; Duan XZ; Liu ZH; Wang YY; You TT; Gao M; Qiao YL; Basu P; Zhao FH
    BMC Med; 2023 Apr; 21(1):149. PubMed ID: 37069602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.
    Vijayaraghavan A; Efrusy MB; Goodman KA; Santas CC; Huh WK
    Gynecol Oncol; 2010 Nov; 119(2):237-42. PubMed ID: 20713299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
    Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
    BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative performance evaluation of different HPV tests and triaging strategies using self-samples and feasibility assessment of thermal ablation in 'colposcopy and treat' approach: A population-based study in rural China.
    Zhao XL; Xu XQ; Duan XZ; Rezhake R; Hu SY; Wang Y; Xia CF; Zhang X; Qiao YL; Sankaranarayanan R; Zhao FH; Basu P
    Int J Cancer; 2020 Sep; 147(5):1275-1285. PubMed ID: 31970767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of HPV-positive women in cervical screening using results from two consecutive screening rounds.
    Polman NJ; Veldhuijzen NJ; Heideman DAM; Snijders PJF; Meijer CJLM; Berkhof J
    Int J Cancer; 2019 May; 144(9):2339-2346. PubMed ID: 30565673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower cost strategies for triage of human papillomavirus DNA-positive women.
    Qiao YL; Jeronimo J; Zhao FH; Schweizer J; Chen W; Valdez M; Lu P; Zhang X; Kang LN; Bansil P; Paul P; Mahoney C; Berard-Bergery M; Bai P; Peck R; Li J; Chen F; Stoler MH; Castle PE
    Int J Cancer; 2014 Jun; 134(12):2891-901. PubMed ID: 24248915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology.
    Termrungruanglert W; Khemapech N; Tantitamit T; Havanond P
    J Gynecol Oncol; 2019 Mar; 30(2):e17. PubMed ID: 30740950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico.
    Torres-Ibarra L; Cuzick J; Lorincz AT; Spiegelman D; Lazcano-Ponce E; Franco EL; Moscicki AB; Mahmud SM; Wheeler CM; Rivera-Paredez B; Hernández-López R; León-Maldonado L; Salmerón J;
    JAMA Netw Open; 2019 Nov; 2(11):e1915781. PubMed ID: 31747033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of different strategies for the triage to colposcopy of women tested high-risk HPV positive on self-collected cervicovaginal samples.
    Chatzistamatiou K; Tsertanidou A; Moysiadis T; Mouchtaropoulou E; Pasentsis K; Skenderi A; Stamatopoulos K; Agorastos T
    Gynecol Oncol; 2021 Sep; 162(3):560-568. PubMed ID: 34210517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model-based analysis.
    Portnoy A; Pedersen K; Sy S; Tropé A; Engesaeter B; Kim JJ; Burger EA
    Int J Cancer; 2024 Mar; 154(6):1073-1081. PubMed ID: 38088449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
    Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
    BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis.
    Choi HCW; Leung K; Chan KKL; Bai Y; Jit M; Wu JT
    BMC Med; 2023 Feb; 21(1):48. PubMed ID: 36765349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
    Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
    BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining Optimal Triage Strategies for hrHPV Screen-Positive Women-An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry.
    Stanczuk GA; Baxter GJ; Currie H; Forson W; Lawrence JR; Cuschieri K; Wilson A; Patterson L; Govan L; Black J; Palmer T; Arbyn M
    Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1629-1635. PubMed ID: 28887297
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
    Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
    BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Performance of vaginal self-sampling high-risk HPV genotyping as primary and combining cytology or viral load as secondary in cervical cancer screening].
    Guo CL; Luo HX; Wang C; Qu XF; Yang B; Belinson JL; Du H; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2021 Apr; 56(4):271-279. PubMed ID: 33902239
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.